These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 19626705)

  • 21. Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative.
    Wajant H; Moosmayer D; Wüest T; Bartke T; Gerlach E; Schönherr U; Peters N; Scheurich P; Pfizenmaier K
    Oncogene; 2001 Jul; 20(30):4101-6. PubMed ID: 11494138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improving biophysical properties of a bispecific antibody scaffold to aid developability: quality by molecular design.
    Von Kreudenstein TS; Escobar-Carbrera E; Lario PI; D'Angelo I; Brault K; Kelly J; Durocher Y; Baardsnes J; Woods RJ; Xie MH; Girod PA; Suits MD; Boulanger MJ; Poon DK; Ng GY; Dixit SB
    MAbs; 2013; 5(5):646-54. PubMed ID: 23924797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells.
    Kellner C; Bruenke J; Stieglmaier J; Schwemmlein M; Schwenkert M; Singer H; Mentz K; Peipp M; Lang P; Oduncu F; Stockmeyer B; Fey GH
    J Immunother; 2008; 31(9):871-84. PubMed ID: 18833000
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular dynamics simulations highlight mobile regions in proteins: A novel suggestion for converting a murine V(H) domain into a more tractable species.
    Voordijk S; Hansson T; Hilvert D; van Gunsteren WF
    J Mol Biol; 2000 Jul; 300(4):963-73. PubMed ID: 10891281
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin.
    Wu C; Ying H; Grinnell C; Bryant S; Miller R; Clabbers A; Bose S; McCarthy D; Zhu RR; Santora L; Davis-Taber R; Kunes Y; Fung E; Schwartz A; Sakorafas P; Gu J; Tarcsa E; Murtaza A; Ghayur T
    Nat Biotechnol; 2007 Nov; 25(11):1290-7. PubMed ID: 17934452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incorporating receptor flexibility in the molecular design of protein interfaces.
    Li L; Liang S; Pilcher MM; Meroueh SO
    Protein Eng Des Sel; 2009 Sep; 22(9):575-86. PubMed ID: 19643976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens.
    Moore GL; Bautista C; Pong E; Nguyen DH; Jacinto J; Eivazi A; Muchhal US; Karki S; Chu SY; Lazar GA
    MAbs; 2011; 3(6):546-57. PubMed ID: 22123055
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Observation of "ionic lock" formation in molecular dynamics simulations of wild-type beta 1 and beta 2 adrenergic receptors.
    Vanni S; Neri M; Tavernelli I; Rothlisberger U
    Biochemistry; 2009 Jun; 48(22):4789-97. PubMed ID: 19378975
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current perspectives of bispecific antibody-based immunotherapy.
    Talac R; Nelson H
    J Biol Regul Homeost Agents; 2000; 14(3):175-81. PubMed ID: 11037049
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Domain interactions in the Fab fragment: a comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability.
    Röthlisberger D; Honegger A; Plückthun A
    J Mol Biol; 2005 Apr; 347(4):773-89. PubMed ID: 15769469
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics.
    Kipriyanov SM; Moldenhauer G; Schuhmacher J; Cochlovius B; Von der Lieth CW; Matys ER; Little M
    J Mol Biol; 1999 Oct; 293(1):41-56. PubMed ID: 10512714
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phage diabody repertoires for selection of large numbers of bispecific antibody fragments.
    McGuinness BT; Walter G; FitzGerald K; Schuler P; Mahoney W; Duncan AR; Hoogenboom HR
    Nat Biotechnol; 1996 Sep; 14(9):1149-54. PubMed ID: 9631069
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new approach to produce IgG
    Zhao C; Zhang W; Gong G; Xie L; Wang MW; Hu Y
    Sci Rep; 2021 Sep; 11(1):18630. PubMed ID: 34545109
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments.
    Reiter Y; Brinkmann U; Lee B; Pastan I
    Nat Biotechnol; 1996 Oct; 14(10):1239-45. PubMed ID: 9631086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2.
    Smith MR; Jin F; Joshi I
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5528s-5534s. PubMed ID: 17875785
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bispecific antibody derivatives based on full-length IgG formats.
    Grote M; Haas AK; Klein C; Schaefer W; Brinkmann U
    Methods Mol Biol; 2012; 901():247-63. PubMed ID: 22723106
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Conserved amino acid networks involved in antibody variable domain interactions.
    Wang N; Smith WF; Miller BR; Aivazian D; Lugovskoy AA; Reff ME; Glaser SM; Croner LJ; Demarest SJ
    Proteins; 2009 Jul; 76(1):99-114. PubMed ID: 19089973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor-necrosis-factor-related apoptosis-inducing ligand and the regulation of hematopoiesis.
    Secchiero P; Zauli G
    Curr Opin Hematol; 2008 Jan; 15(1):42-8. PubMed ID: 18043245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Humanization of a highly stable single-chain antibody by structure-based antigen-binding site grafting.
    Villani ME; Morea V; Consalvi V; Chiaraluce R; Desiderio A; Benvenuto E; Donini M
    Mol Immunol; 2008 May; 45(9):2474-85. PubMed ID: 18313757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapid optimization and prototyping for therapeutic antibody-like molecules.
    Xu L; Kohli N; Rennard R; Jiao Y; Razlog M; Zhang K; Baum J; Johnson B; Tang J; Schoeberl B; Fitzgerald J; Nielsen U; Lugovskoy AA
    MAbs; 2013; 5(2):237-54. PubMed ID: 23392215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.